Stereotactic Ablative RT in HCC
Colorectal Cancer Research & Treatment News - recap from the May 2014 ASCO conference
A Phase I Study of MK-2206, an Oral Potent Allosteric Akt Inhibitor in Patients with Advanced Solid Tumors Anthony W. Tolcher, 1 Timothy A. Yap, 2 Ivy.
Toward More Aggressive Management of Neuroendocrine Tumors: Current and Future Perspectives Moderator: Ashley Grossman, MD, FRCP Professor of Neuroendocrinology.
II-SDV 2014 Development of Reports and Visualisations to Facilitate the Analysis and Transformation of the Clinical Trial Landscape into Actionable Intelligence (Diane Webb - Bizint,
Talimogene laherparepvec (T-VEC, OncoVEX GM-CSF) phase 3 data in melanoma presented at virotherapy symposium Oxford, April 2014
07 state of the art of the management of advanced and recurrent ovarian cancer
Pfizer at Lehman Brothers Global Health Care Conference
FOLFOXIRI plus bevacizumab (bev) vs FOLFIRI plus bev as 1st-line treatment of metastatic colorectal cancer: results of the phase III randomized TRIBE trial.
1. DLBCL of the elderly in age older than life expectancy the single institute experience in Taiwan Sheng Hsuan,Chien, MD Division of Hematology and Oncology,
A pooled analysis of the final results of the two randomized phase II studies comparing Gemcitabine (G) vs Gemcitabine + Docetaxel (G+D) in patients (pts)
CALGB 80403 / ECOG 1206: Randomized Phase II Study of Standard Chemotherapy + Cetuximab for Metastatic Esophageal Cancer PC Enzinger, BA Burtness, DR Hollis,